Hoersholm, Denmark; May 12th, 2016 – Medical Prognosis Institute A/S announces that positive data on their Drug Response Predictor (DRP), has been published in the journal PLOS ONE with the title: “Cell line derived 5-FU and irinotecan drug-sensitivity profiles evaluated in adjuvant colon cancer trial data.” Data from a prospective randomized clinical trial was analyzed with the unique DRP tool. The DRP(TM) for 5-FU could identify which patients benefitted from treatment with 5-FU. When looking at overall survival the patients with the most positive predictor have twice the survival rate of the patients with poor prediction.
“The publication in PLOS ONE is an another important mile stone documenting the solid data on the Drug Response Predictor – DRP(TM) – both demonstrated in prospective, retrospective and blinded clinical studies – this time in collaboration with an international well known academic group. All calculations were done by external researchers that are independent from MPI” said Adjunct professor Peter Buhl Jensen, M.D., DMSc and CEO of Medical Prognosis Institute.
“5-FU is one of the most important chemotherapeutics which is widely used around the world – and yet there is until now no biomarker in clinic to tell whether a patient is likely to benefit from the treatment or not. I believe that the specific 5-FU DRP(TM) has potential to increase the survival rate of cancer patients” Peter Buhl Jensen further added.
In this international collaboration between MPI and two independent public science groups gene expression from tumors from 636 stage III colon cancer patients was evaluated. Conclusion was that “The 5-FU predictor was prognostic in stage III patients in PETACC-3 but not in stage II patients with no adjuvant therapy. This suggests a potential predictive ability of the 5-FU sensitivity profile to identify colon cancer patients who may benefit from 5-FU.”
Selected data from the publication shows that the 5-FU specific DRP(TM) in PETACC-3 showed a statistically significant association with relapse free survival (RFS) (hazard ratio (HR) = 0.54 (0.41-0.71), p<1e-05) and overall survival (HR = 0.47 (0.34-0.63), p<1e-06). The effect of the 5-FU profile remained significant in a multivariable model, adjusting for several relevant clinical and tissue specific parameters.
Please find the full publication on: PLOS ONE
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI’s exceptional opportunity to personalize cancer treatment – begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI’s DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.
About MPI’s multiple biomarker called Drug Response Predictor – DRP(TM)
MPI’s DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anti-cancer drug. In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. MicroRNA is used on certain products whereas the messengerRNA is more broadly useable and more validated. The DRP(TM) platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.
For further information, please contact
CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.d.
Phone: +45 21 60 89 2
Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark